Open label, uncontrolled study of XRP9881 [larotaxel] in combination with trastuzumab (Herceptin) in patients with HER2 positive metastatic breast cancer (MBC).
Phase of Trial: Phase II
Latest Information Update: 12 Jun 2013
At a glance
- Drugs Larotaxel (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 11 Apr 2011 Actual end date changed from Dec 2010 to Jan 2011 as reported by ClinicalTrials.gov.
- 18 Jan 2011 Actual end date (December 2010) added as reported by ClinicalTrials.gov.
- 18 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.